Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older-Reference-Cited by-同舟云学术

Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older

Published:2016-06 Issue:30 Volume:34 Page:3454-3462
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Frenck Robert W.,Fiquet Anne,Gurtman Alejandra,van Cleeff Martin,Davis Matthew,Rubino John,Smith William,Sundaraiyer Vani,Sidhu Mohinder,Emini Emilio A.,Gruber William C.,Scott Daniel A.,Schmoele-Thoma Beate

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference21 articles.

1. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits;Jansen;Vaccine,2009

2. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era;Robinson;JAMA,2001

3. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment;Kothe;Eur Respir J,2008

4. Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study;Ricketson;PLoS ONE,2013

5. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells;Clutterbuck;J Infect Dis,2012

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023;MMWR. Recommendations and Reports;2023-09-08

2. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia;Vaccine;2023-05

3. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial;Vaccine;2023-03

4. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination;Vaccine;2021-12

5. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU);Human Vaccines & Immunotherapeutics;2021-11-02